eNewsroom for: Pathogenica Inc.

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/Pathogenica Inc.//Screen shot 2011-08-02 at 11.43.00 AM.png

Pathogenica Inc. Company Profile

Pathogenica, based in Cambridge, MA, was founded in 2009 to pioneer commercial applications of pathogen sequencing. Pathogenica applies next generation DNA sequencing technology for rapid multiplex identification of pathogens, drug resistance genes, and toxins in patient samples. The founding scientific advisory board (SAB) is comprised of distinguished scientists in the field, including George Church, Harvard Medical School; Ron Davis, Stanford University; W. Ian Lipkin, Columbia University; Andrew Onderdonk, Harvard Medical School; and Kun Zhang, University of California. Pathogenica's high throughput pathogen detection system is expected to enable rapid and highly sensitive detection of a wide variety of pathogens from patient samples using just a common assay protocol.

News from Pathogenica Inc.:

Pathogenica Achieves CE Marking for HAI BioDetection Kit

BOSTON, Aug. 14, 2013 /PRNewswire/ — Pathogenica, Inc. (www.pathogenica.com) announced today that the company has achieved the CE mark under the European Directive on In Vitro Diagnostic Medical Devices for its HAI BioDetection kit that runs on the Ion PGM™ benchtop sequencer.  Thi…

Pathogenica Signs Agreement with Illumina

Companies to co-market Pathogenica HAI kit for MiSeq in Asia Pacific BOSTON, July 17, 2013 /PRNewswire/ — Pathogenica Inc. announced today it had entered into an agreement with Illumina, whereby the parties will co-market in the Asia Pacific region a new version of Pathogenica's HAI Bio…

Pathogenica CSO Speaks at IBC Life Sciences Drug Discovery & Diagnostic Development Week

CAMBRIDGE, Mass., Aug. 2, 2011 — Pathogenica, Inc. announced that the Company's Chief Scientific Officer, Graeme Doran, Ph.D., is speaking today at the IBC Life Sciences Drug Discovery & Diagnostic Development Week, in San Francisco. During the conference, the only event on the appl…